Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06968845 | A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis | PHASE2 | RECRUITING | 120 | — | — | Feb 2, 2026 | Dec 31, 2027 | Jun 5, 2026 | 16 | United States, Australia +2 |
| Arm | Type | Description |
|---|---|---|
| (1) 2.5 mg LTI-03 capsule BID | EXPERIMENTAL | Caveolin-1-Scaffolding-Protein-Derived Peptide |
| (2) 2.5 mg LTI-03 capsules BID | EXPERIMENTAL | Caveolin-1-Scaffolding-Protein-Derived Peptide |
| (1) Placebo capsule BID | PLACEBO_COMPARATOR | Lactose powder |
| (2) Placebo capsules BID | PLACEBO_COMPARATOR | Lactose powder |
| Name | Type | Description |
|---|---|---|
| LTI-03 | DRUG | Caveolin-1-Scaffolding-Protein-Derived Peptide |
| Dry Powder Inhaler | DEVICE | Plastiape Monodose RS01 Model 7 |
| Placebo | DRUG | Lactose powder |
Inclusion Criteria: 1. Male or female age 40 years or older. 2. Willing and able to provide written informed consent. 3. Diagnosis of IPF within 5 years of Screening as confirmed by a centrally read HRCT of the chest as defined by the ATS/ERS/JRS/ALAT guideline. HRCT lung fibrosis by central read d...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 2 | PHASE3 | BMS-986278 |
| United Therapeutics Corporation | UTHR | 2 | PHASE3 | Treprostinil |
| PureTech Health PLC Sponsored ADR | PRTC | 2 | PHASE3 | Deupirfenidone, Pirfenidone |
| AbbVie, Inc. | ABBV | 2 | PHASE2 | ABBV-142 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE2 | Axatilimab |
| Contineum Therapeutics, Inc. Class A | CTNM | 1 | PHASE2 | PIPE-791 Dose A, PIPE-791 Dose B |
| Rein Therapeutics, Inc | RNTX | 1 | PHASE2 | LTI-03 |
| Cumberland Pharmaceuticals Inc. | CPIX | 1 | PHASE2 | Ifetroban |
| Avalyn Pharma Inc | AVLN | 3 | PHASE2 | AP02, AP01 |
| MannKind Corporation | MNKD | 1 | PHASE1 | MNKD-201 |
| Trevi Therapeutics, Inc. | TRVI | 1 | PHASE1 | NAL |
| AgomAb Therapeutics NV ADR | AGMB | 1 | PHASE1 | AGMB-447 |